Related Experiment Videos

Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety

E Korn-Merker1, P Borusiak, H E Boenigk

  • 1Kinderklinik Kidron, Epilepsiezentrum Bethel, Bielefeld, Germnany. kme@neuro.mara.de

Epilepsy Research
|December 22, 1999
PubMed

Insights

Gabapentin (GBP) was evaluated for pediatric partial epilepsy. While generally safe, gabapentin showed disappointing efficacy in reducing refractory partial seizures in children.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Pharmacology

Background:

  • Refractory partial epilepsy in children presents significant treatment challenges.
  • Exploring novel antiepileptic drugs is crucial for improving patient outcomes.

Purpose of the Study:

  • To assess the efficacy and safety of gabapentin (GBP) as an add-on therapy for pediatric partial epilepsy.
  • To determine the effectiveness of GBP in reducing seizure frequency in children with refractory epilepsy.

Main Methods:

  • A prospective, open-label, add-on study was conducted.
  • 52 children and adolescents with refractory partial seizures participated.
  • Gabapentin was administered alongside existing antiepileptic drugs.

Main Results:

  • Gabapentin was generally well-tolerated, with doses ranging from 26-78 mg/kg/day.
  • Seizure frequency remained unchanged in 65% of patients.
  • An initial benefit (seizure reduction ≥50%) was observed in 29% of patients, but tolerance developed in most.

Conclusions:

  • Gabapentin demonstrates a favorable safety profile in pediatric patients.
  • The efficacy of gabapentin for refractory partial seizures in children was found to be disappointing.
  • Further research may be needed to identify optimal treatment strategies for this population.
Abstract

Related Concept Videos